Your browser doesn't support javascript.
loading
Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma.
Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A; Ablain, Julien; Yang, Song; Saint-André, Violaine; Fan, Zi Peng; Do, Brian T; Laga, Alvaro C; Fujinaga, Koh; Santoriello, Cristina; Greer, Celeste B; Kim, Yoon Jung; Clohessy, John G; Bothmer, Anne; Pandell, Nicole; Avagyan, Serine; Brogie, John E; van Rooijen, Ellen; Hagedorn, Elliott J; Shyh-Chang, Ng; White, Richard M; Price, David H; Pandolfi, Pier Paolo; Peterlin, B Matija; Zhou, Yi; Kim, Tae Hoon; Asara, John M; Chang, Howard Y; Young, Richard A; Zon, Leonard I.
Afiliação
  • Tan JL; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Fogley RD; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Flynn RA; Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Ablain J; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Yang S; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Saint-André V; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
  • Fan ZP; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
  • Do BT; Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Laga AC; Department of Pathology, Brigham & Women's Hospital, Boston, MA 02215, USA.
  • Fujinaga K; Departments of Medicine, Microbiology, and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Santoriello C; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Greer CB; Department of Pharmacology, School of Medicine, Yale University, New Haven, CT 06520, USA.
  • Kim YJ; Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX 75080, USA.
  • Clohessy JG; Cancer Research Institute, Beth Israel Deaconess Cancer Center, and Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA; Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center, Harvard Medical School, B
  • Bothmer A; Cancer Research Institute, Beth Israel Deaconess Cancer Center, and Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
  • Pandell N; Preclinical Murine Pharmacogenetics Facility, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
  • Avagyan S; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Brogie JE; Department of Biochemistry, University of Iowa, Iowa City, IA 52242, USA.
  • van Rooijen E; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Hagedorn EJ; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Shyh-Chang N; Genome Institute of Singapore, 60 Biopolis Street, Singapore 138672, Singapore.
  • White RM; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA.
  • Price DH; Department of Biochemistry, University of Iowa, Iowa City, IA 52242, USA.
  • Pandolfi PP; Cancer Research Institute, Beth Israel Deaconess Cancer Center, and Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
  • Peterlin BM; Departments of Medicine, Microbiology, and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Zhou Y; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
  • Kim TH; Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX 75080, USA.
  • Asara JM; Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Chang HY; Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Young RA; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
  • Zon LI; Howard Hughes Medical Institute, Stem Cell Program and Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Cambridge, MA 0213
Mol Cell ; 62(1): 34-46, 2016 Apr 07.
Article em En | MEDLINE | ID: mdl-27058786
ABSTRACT
Studying cancer metabolism gives insight into tumorigenic survival mechanisms and susceptibilities. In melanoma, we identify HEXIM1, a transcription elongation regulator, as a melanoma tumor suppressor that responds to nucleotide stress. HEXIM1 expression is low in melanoma. Its overexpression in a zebrafish melanoma model suppresses cancer formation, while its inactivation accelerates tumor onset in vivo. Knockdown of HEXIM1 rescues zebrafish neural crest defects and human melanoma proliferation defects that arise from nucleotide depletion. Under nucleotide stress, HEXIM1 is induced to form an inhibitory complex with P-TEFb, the kinase that initiates transcription elongation, to inhibit elongation at tumorigenic genes. The resulting alteration in gene expression also causes anti-tumorigenic RNAs to bind to and be stabilized by HEXIM1. HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression. Our study reveals an important role for HEXIM1 in coupling nucleotide metabolism with transcriptional regulation in melanoma.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Proteínas de Ligação a RNA / Fator B de Elongação Transcricional Positiva / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Proteínas de Ligação a RNA / Fator B de Elongação Transcricional Positiva / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article